Medarex Announces Presentations on UltiMAb(R) Antibodies at 71st Annual Meeting of the American College of Rheumatology

PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ — Medarex, Inc. announced today that at least five antibodies generated from Medarex’s UltiMAb(R) technology in which Medarex wholly owns or has an economic interest through co-promote/profit sharing rights, royalties and/or equity ownership, are expected to be the subject of oral or poster presentations at the 71st Annual Meeting of the American College of Rheumatology (ACR), being held November 6-11, 2007 in Boston.

Golimumab (CNTO 148) and ustekinumab (CNTO 1275) Phase III or Phase II clinical data for inflammatory diseases in development by Medarex’s licensing partner, Centocor, Inc.

   — “Golimumab, a new, human TNF-alpha antibody administered as a monthly      subcutaneous injection in ankylosing spondylitis (AS): 24-week efficacy      and safety results of the randomized, placebo-controlled GO-RAISE      study” (Presentation #L10, Spondylarthropathies and Psoriatic Arthritis      Session) – Poster presentation scheduled for Thursday, November 8, 2007      at 8:00 A.M.    — “Characterization of golimumab (CNTO 148), a novel monoclonal antibody      specific for human TNFa” (Presentation #274, RA Treatment: Small      Molecules Sessions) – Poster presentation scheduled for Thursday,      November 8, 2007 at 8:00 A.M.    — “Phase II, randomized, placebo-controlled study of CNTO 1275, a human      interleukin-12/23 monoclonal antibody, in psoriatic arthritis”      (Presentation #L16, Spondylarthropathies and Psoriatic Arthritis      Session) – Oral presentation scheduled for Saturday, November 10, 2007      at 3:15 P.M.    — “Golimumab, a new human TNF-alpha antibody administered as a monthly      subcutaneous injection in psoriatic arthritis: 24-week efficacy and      safety results of the randomized, placebo-controlled GO-REVEAL study”      (Presentation #L14, Spondylarthropathies and Psoriatic Arthritis      Session) – Oral presentation scheduled for Saturday, November 10, 2007      at 2:45 P.M.   

On November 1, 2007, Johnson & Johnson announced that it will sponsor an analyst meeting and webcast on Thursday, November 8, 2007, from 5:00-6:00 P.M. Eastern Time to discuss late-stage compounds, including golimumab and ustekinumab.

Ofatumumab (HuMax-CD20) Phase II clinical data for rheumatoid arthritis in development by Medarex’s licensing partner, Genmab A/S

   — “Ofatumumab, a human CD20 monoclonal antibody, in the treatment of      rheumatoid arthritis: early results from an ongoing, double-blind,      randomized, placebo controlled clinical trial” (Presentation #2086, RA      Treatment: Small Molecules Session) – Poster presentation scheduled for      Saturday, November 10, 2007 at 3:00 P.M.   

MEDI-545 Phase I clinical data for systemic lupus erythematosus in development by Medarex’s partner, MedImmune, Inc.

   — “Safety of MEDI-545, an anti-interferon-. monoclonal antibody, in      MI-CP126, a phase I study in systemic lupus erythematosus (SLE)”      (Presentation #428, SLE Session) – Poster presentation scheduled for      Thursday, November 8, 2007 at 8:00 A.M.    — “Neutralization of type I IFN inducible genes in phase I trial of      anti-IFNa mAb for the treatment of SLE: utility as pharmacodynamic      markers” (Presentation #429, SLE Session) – Poster presentation      scheduled for Thursday, November 8, 2007 at 8:00 A.M.    — “Anti-IFN-a antibody neutralization of early and late transcriptional      responses in PBMC stimulated with serum from SLE patients”      (Presentation #840, Genetics, Genomics and Proteomics Session) – Poster      presentation scheduled for Friday, November 9, 2007 at 8:00 A.M.    — “MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence      of clinical activity in systemic lupus erythematosus” (Presentation      #1315, SLE Session) – Oral presentation scheduled for Friday, November      9, 2007 at 2:30 P.M.    Preclinical data for an anti-CD70 antibody in development by Medarex   — “Functional blocking and targeted depletion of activated lymphocytes by      fucosylated and non-fucosylated fully human anti-CD70 IgG1″      (Presentation #1984, T-cell Biology and Targets in Autoimmune Disease      Session) – Poster presentation scheduled for Saturday, November 10,      2007 at 8:00 A.M.   

Abstracts and information about the ACR and its Annual Meeting may be found at http://www.rheumatology.org/.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world’s unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com/.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

Medarex, Inc.

CONTACT: Media, Jean Mantuano, Corporate Communications, Inc., x2221, orInvestor Relations, Laura S. Choi, x2216, both of Medarex, Inc.,+1-609-430-2880

Web site: http://www.medarex.com/

Company News On-Call: http://www.prnewswire.com/comp/108265.html